Table 1 Initial management of the entire study group
ID | Pathology* | Initial metastatic status | Local staging | Post-operative CTH regimen | Received RTH |
|---|---|---|---|---|---|
1 | FH | NO | III | EE4A | No |
2 | FH | NO | III | WTS 1 ** | Yes |
3 | UFH | NO | III | Regimen M | Yes |
4 | UFH | Lung | III | DD4A | Yes |
5 | FH | NO | II | EE4A | No |
6 | FH | NO | I | No | No |
7 | FH | lung | III | Regimen M | Yes |
8 | FH | Lung and liver | III | Regimen M | Yes*** |
9 | FH | NO | III | EE4A | No |
10 | FH | NO | III | EE4A | No |
11 | UFH | NO | I | NA | No |
12 | FH | Lung | II | DD4A | Yes |
13 | FH | NO | II | NO | No |
14 | FH | Lung | III | DD4A | Yes*** |
15 | FH | NO | III | DD4A /Vp16 Cyclo/Carbo | Yes |
16 | FH | NO | III | DD4A | Yes |
17 | UFH | NO | III | DD4A | Yes |
18 | UFH | NO | I | EE4A | No |
19 | FH | NO | III | DD4A/Regimen M | Yes |
20 | FH | NO | III | VCR/COS | Yes*** |
21 | FH | Lung | III | WTS 1 2000* | Yes |
22 | FH | NO | I | VCR/COS/ VCR/ADR | No |
23 | FH | NO | I | EE4A | No |
24 | FH | NO | III | DD4A | Yes |
25 | FH | NO | II | DD4A | No |
26 | FH | NO | I | EE4A | No |
27 | UFH | NO | III | DD4A | Yes |
28 | FH | Lung and liver | III | DD4A | Yes |
29 | FH | NO | I | EE4A | No |
30 | UFH | Lung | III | DD4A | Yes |